C. Zhou Et Al. , "A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)," Cancer cell , vol.42, no.2, pp.198-208, 2024
Zhou, C. Et Al. 2024. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer cell , vol.42, no.2 , 198-208.
Zhou, C., Hu, Y., Arkania, E., Kilickap, S., Ying, K., Xu, F., ... Wu, L.(2024). A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer cell , vol.42, no.2, 198-208.
Zhou, Caicun Et Al. "A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)," Cancer cell , vol.42, no.2, 198-208, 2024
Zhou, Caicun Et Al. "A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)." Cancer cell , vol.42, no.2, pp.198-208, 2024
Zhou, C. Et Al. (2024) . "A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)." Cancer cell , vol.42, no.2, pp.198-208.
@article{article, author={Caicun Zhou Et Al. }, title={A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)}, journal={Cancer cell}, year=2024, pages={198-208} }